Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Fmr LLC

FMR LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 742,305 shares of the specialty pharmaceutical company's stock after selling 93,576 shares during the period. FMR LLC owned 1.23% of Jazz Pharmaceuticals worth $91,415,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of JAZZ. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after buying an additional 115,102 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Jazz Pharmaceuticals by 4.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after acquiring an additional 72,007 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after purchasing an additional 48,708 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 15.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after purchasing an additional 83,807 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Jazz Pharmaceuticals by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after purchasing an additional 24,481 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. HC Wainwright lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 2.4 %

NASDAQ:JAZZ traded down $2.44 during mid-day trading on Monday, reaching $100.34. The stock had a trading volume of 610,833 shares, compared to its average volume of 788,786. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $6.09 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The stock's 50 day simple moving average is $126.90 and its two-hundred day simple moving average is $122.44.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.